Tonix reports Phase 1 data for TNX-1500 anti-CD40L antibody in healthy adults, supports monthly IV dosing

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

TNXP

0.00
  • Tonix Pharmaceuticals announced peer-reviewed publication of Phase 1 data for TNX-1500, an investigational antibody aimed at preventing transplant rejection.
  • Results were presented as published Phase 1 findings, showing the drug was generally well tolerated with no serious safety issues reported.
  • The study also showed biological activity consistent with suppressing immune responses, supporting continued development in transplant and autoimmune settings.
  • An investigator-initiated Phase 2 kidney transplant study at Massachusetts General Hospital is expected to start in 2H 2026, pending FDA clearance of an IND.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270700PRIMZONEFULLFEED9726674) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.